Resistance of γA/γ' fibrin clots to fibrinolysis

Lisa A. Falls, David Farrell

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Elevated plasma fibrinogen levels are a major risk factor for thrombosis. This report shows two mechanisms by which fibrinogen can affect the fibrinolysis rate in vitro and thus may lead to thrombosis. First, the lysis rate of fibrin decreases as the initial concentration of fibrinogen increases. Second, a minor variant form of fibrinogen decreases the rate of fibrinolysis. This variant, γA/γ' fibrinogen, has one altered γ chain and is known to bind to factor XIII zymogen. In a fibrinolysis assay containing purified thrombin, fibrinogen, tissue-type plasminogen activator, and plasminogen, clots from γA/γA and γA/γ' fibrinogen lysed at similar rates. However, when factor XIII was added, slower lysis was seen in γA/γ' fibrin clots when compared with γA/γA fibrin clots. A D-dimer agglutination assay showed that the γA/γ' clots were more highly cross-linked than the γA/γA clots. The lysis rates of γA/γ' clots were similar to γA/γA clots in the presence of N-ethylmaleimide, a specific inhibitor of factor XIIIa. The γA/γ' fibrin clots made in the presence of factor XIII showed increased proteolytic resistance to both plasmin and trypsin. Clots made from afibrinogenemic plasma reconstituted with γA/γ' fibrinogen also showed significant resistance to lysis compared with γA/γA fibrinogen. These data demonstrate γA/γ' fibrin is resistant to fibrinolysis, possibly as a result of concentrating factor XIII on the clot. The total fibrinogen concentration and the amount of γA/γ' fibrinogen increase clot stability in vitro and thus may contribute independently to the risk of thrombosis in humans.

Original languageEnglish (US)
Pages (from-to)14251-14256
Number of pages6
JournalJournal of Biological Chemistry
Volume272
Issue number22
DOIs
StatePublished - May 30 1997
Externally publishedYes

Fingerprint

Fibrinolysis
Fibrin
Fibrinogen
Factor XIII
Thrombosis
Assays
Factor XIIIa
Plasmas
Enzyme Precursors
Ethylmaleimide
Plasminogen
Fibrinolysin
Agglutination
Tissue Plasminogen Activator
Thrombin
Trypsin

ASJC Scopus subject areas

  • Biochemistry

Cite this

Resistance of γA/γ' fibrin clots to fibrinolysis. / Falls, Lisa A.; Farrell, David.

In: Journal of Biological Chemistry, Vol. 272, No. 22, 30.05.1997, p. 14251-14256.

Research output: Contribution to journalArticle

Falls, Lisa A. ; Farrell, David. / Resistance of γA/γ' fibrin clots to fibrinolysis. In: Journal of Biological Chemistry. 1997 ; Vol. 272, No. 22. pp. 14251-14256.
@article{5ba89d8ac1344d03ac06bfe9a9518cf3,
title = "Resistance of γA/γ' fibrin clots to fibrinolysis",
abstract = "Elevated plasma fibrinogen levels are a major risk factor for thrombosis. This report shows two mechanisms by which fibrinogen can affect the fibrinolysis rate in vitro and thus may lead to thrombosis. First, the lysis rate of fibrin decreases as the initial concentration of fibrinogen increases. Second, a minor variant form of fibrinogen decreases the rate of fibrinolysis. This variant, γA/γ' fibrinogen, has one altered γ chain and is known to bind to factor XIII zymogen. In a fibrinolysis assay containing purified thrombin, fibrinogen, tissue-type plasminogen activator, and plasminogen, clots from γA/γA and γA/γ' fibrinogen lysed at similar rates. However, when factor XIII was added, slower lysis was seen in γA/γ' fibrin clots when compared with γA/γA fibrin clots. A D-dimer agglutination assay showed that the γA/γ' clots were more highly cross-linked than the γA/γA clots. The lysis rates of γA/γ' clots were similar to γA/γA clots in the presence of N-ethylmaleimide, a specific inhibitor of factor XIIIa. The γA/γ' fibrin clots made in the presence of factor XIII showed increased proteolytic resistance to both plasmin and trypsin. Clots made from afibrinogenemic plasma reconstituted with γA/γ' fibrinogen also showed significant resistance to lysis compared with γA/γA fibrinogen. These data demonstrate γA/γ' fibrin is resistant to fibrinolysis, possibly as a result of concentrating factor XIII on the clot. The total fibrinogen concentration and the amount of γA/γ' fibrinogen increase clot stability in vitro and thus may contribute independently to the risk of thrombosis in humans.",
author = "Falls, {Lisa A.} and David Farrell",
year = "1997",
month = "5",
day = "30",
doi = "10.1074/jbc.272.22.14251",
language = "English (US)",
volume = "272",
pages = "14251--14256",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "22",

}

TY - JOUR

T1 - Resistance of γA/γ' fibrin clots to fibrinolysis

AU - Falls, Lisa A.

AU - Farrell, David

PY - 1997/5/30

Y1 - 1997/5/30

N2 - Elevated plasma fibrinogen levels are a major risk factor for thrombosis. This report shows two mechanisms by which fibrinogen can affect the fibrinolysis rate in vitro and thus may lead to thrombosis. First, the lysis rate of fibrin decreases as the initial concentration of fibrinogen increases. Second, a minor variant form of fibrinogen decreases the rate of fibrinolysis. This variant, γA/γ' fibrinogen, has one altered γ chain and is known to bind to factor XIII zymogen. In a fibrinolysis assay containing purified thrombin, fibrinogen, tissue-type plasminogen activator, and plasminogen, clots from γA/γA and γA/γ' fibrinogen lysed at similar rates. However, when factor XIII was added, slower lysis was seen in γA/γ' fibrin clots when compared with γA/γA fibrin clots. A D-dimer agglutination assay showed that the γA/γ' clots were more highly cross-linked than the γA/γA clots. The lysis rates of γA/γ' clots were similar to γA/γA clots in the presence of N-ethylmaleimide, a specific inhibitor of factor XIIIa. The γA/γ' fibrin clots made in the presence of factor XIII showed increased proteolytic resistance to both plasmin and trypsin. Clots made from afibrinogenemic plasma reconstituted with γA/γ' fibrinogen also showed significant resistance to lysis compared with γA/γA fibrinogen. These data demonstrate γA/γ' fibrin is resistant to fibrinolysis, possibly as a result of concentrating factor XIII on the clot. The total fibrinogen concentration and the amount of γA/γ' fibrinogen increase clot stability in vitro and thus may contribute independently to the risk of thrombosis in humans.

AB - Elevated plasma fibrinogen levels are a major risk factor for thrombosis. This report shows two mechanisms by which fibrinogen can affect the fibrinolysis rate in vitro and thus may lead to thrombosis. First, the lysis rate of fibrin decreases as the initial concentration of fibrinogen increases. Second, a minor variant form of fibrinogen decreases the rate of fibrinolysis. This variant, γA/γ' fibrinogen, has one altered γ chain and is known to bind to factor XIII zymogen. In a fibrinolysis assay containing purified thrombin, fibrinogen, tissue-type plasminogen activator, and plasminogen, clots from γA/γA and γA/γ' fibrinogen lysed at similar rates. However, when factor XIII was added, slower lysis was seen in γA/γ' fibrin clots when compared with γA/γA fibrin clots. A D-dimer agglutination assay showed that the γA/γ' clots were more highly cross-linked than the γA/γA clots. The lysis rates of γA/γ' clots were similar to γA/γA clots in the presence of N-ethylmaleimide, a specific inhibitor of factor XIIIa. The γA/γ' fibrin clots made in the presence of factor XIII showed increased proteolytic resistance to both plasmin and trypsin. Clots made from afibrinogenemic plasma reconstituted with γA/γ' fibrinogen also showed significant resistance to lysis compared with γA/γA fibrinogen. These data demonstrate γA/γ' fibrin is resistant to fibrinolysis, possibly as a result of concentrating factor XIII on the clot. The total fibrinogen concentration and the amount of γA/γ' fibrinogen increase clot stability in vitro and thus may contribute independently to the risk of thrombosis in humans.

UR - http://www.scopus.com/inward/record.url?scp=0030611710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030611710&partnerID=8YFLogxK

U2 - 10.1074/jbc.272.22.14251

DO - 10.1074/jbc.272.22.14251

M3 - Article

C2 - 9162058

AN - SCOPUS:0030611710

VL - 272

SP - 14251

EP - 14256

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 22

ER -